Advanced search
Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 7, 2022 - Issue 1
Submit an article Journal homepage
662
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Precision oncology in cholangiocarcinoma: current issues in clinical trial design and access to targeted therapies

Alessandro Rizzoa Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia;b Medical Oncology Unit, “Mons. R. Dimiccoli” Hospital, Barletta, ItalyCorrespondence[email protected]
View further author information
,
Angela Dalia Riccia Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia;b Medical Oncology Unit, “Mons. R. Dimiccoli” Hospital, Barletta, ItalyView further author information
,
Gennaro Gadaleta-Caldarolab Medical Oncology Unit, “Mons. R. Dimiccoli” Hospital, Barletta, ItalyView further author information
&
Giovanni Brandia Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItaliaView further author information
Pages 102-104 | Received 22 Jul 2021, Accepted 15 Nov 2021, Published online: 29 Nov 2021

References

  • Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma ‐ evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15:95‐111.
  • Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.
  • Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:353–363.
  • Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–588.
  • Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39:98–107.
  • Rizzo A, Ricci AD, Brandi G. Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun. 2021;27:100337. Epub 2021 Feb 18. PMID: 33611090.
  • Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, et al. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Rev Anticancer Ther. 2020 Sep;20(9):765–773. Epub 2020 Aug 16. PMID: 32757962.
  • Zhang W, Zhou H, Wang Y, et al. Systemic treatment of advanced or recurrent biliary tract cancer. Biosci Trends. 2020 Nov 4;14(5):328–341. Epub 2020 Aug 24. PMID: 32830166.
  • Mahipal A, Kommalapati A, Tella SH, et al. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018 Sep;27(9):709–720. Epub 2018 Aug 30. PMID: 30124336.
  • Rizzo A, Frega G, Ricci AD, et al. Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: a systematic review and meta-analysis. In Vivo. 2020 Mar-Apr;34(2):479–488. PMID: 32111744; PMCID: PMC7157865.
  • Gervaso L, Pellicori S, Fazio N. Ivosidenib for advanced IDH1-mutant cholangiocarcinoma. Lancet Oncol. 2020 Aug;21(8):e370. PMID: 32758465.
  • Ettrich TJ, Schwerdel D, Dolnik A, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019 Sep 13;9(1):13261. PMID: 31519967; PMCID: PMC6744511.
  • Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 Jun;21(6):796–807. Epub 2020 May 13. Erratum in: Lancet Oncol. 2020 Oct;21(10):e462.PMID: 32416072; PMCID: PMC7523268.
  • Zhu AW, Macarulla T, Javle M, et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. J Clin Oncol. 2021;39(3_suppl):266.
  • Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–684.
  • Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 Sep;21(9):1234–1243. Epub 2020 Aug 17. PMID: 32818466.
  • Fabris L, Perugorria MJ, Mertens J, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019 May;39(Suppl 1):63–78. PMID: 30907492.
  • Montal R, Sia D, Montironi C, et al. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020 Aug;73(2):315–327. Epub 2020 Mar 12. PMID: 32173382; PMCID: PMC8418904.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.